327 related articles for article (PubMed ID: 22450392)
41. Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability.
Distler A; Lang V; Del Vecchio T; Huang J; Zhang Y; Beyer C; Lin NY; Palumbo-Zerr K; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2014 Jun; 73(6):1264-8. PubMed ID: 24445254
[TBL] [Abstract][Full Text] [Related]
42. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis.
Hasegawa M; Fujimoto M; Takehara K; Sato S
J Dermatol Sci; 2005 Jul; 39(1):1-7. PubMed ID: 15885984
[TBL] [Abstract][Full Text] [Related]
43. Innovative therapies for systemic sclerosis.
Ong VH; Denton CP
Curr Opin Rheumatol; 2010 May; 22(3):264-72. PubMed ID: 20190640
[TBL] [Abstract][Full Text] [Related]
44. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts.
Wang Y; Fan PS; Kahaleh B
Arthritis Rheum; 2006 Jul; 54(7):2271-9. PubMed ID: 16802366
[TBL] [Abstract][Full Text] [Related]
45. Antifibrotics in systemic sclerosis.
Martin-Lopez M; Carreira PE
Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101671. PubMed ID: 33839046
[TBL] [Abstract][Full Text] [Related]
46. Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta.
Bhattacharyya S; Ghosh AK; Pannu J; Mori Y; Takagawa S; Chen G; Trojanowska M; Gilliam AC; Varga J
Arthritis Rheum; 2005 Apr; 52(4):1248-58. PubMed ID: 15818659
[TBL] [Abstract][Full Text] [Related]
47. Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis.
Korman B
Transl Res; 2019 Jul; 209():77-89. PubMed ID: 30876809
[TBL] [Abstract][Full Text] [Related]
48. Targeting fibrosis in systemic sclerosis.
Lafyatis R
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):395-400. PubMed ID: 17214585
[TBL] [Abstract][Full Text] [Related]
49. [Do specific antifibrotic properties of immunosuppressive drugs used in the treatment of systemic sclerosis exist?].
Verrecchia F; Michel L; Keshtmand H; Wang Y; Launay D; Farge D
Rev Med Interne; 2009 Nov; 30(11):955-62. PubMed ID: 19349102
[TBL] [Abstract][Full Text] [Related]
50. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies.
Asano Y; Varga J
Semin Cell Dev Biol; 2020 May; 101():146-160. PubMed ID: 31859147
[TBL] [Abstract][Full Text] [Related]
51. Emerging diagnostic and therapeutic challenges for skin fibrosis in systemic sclerosis.
Abraham D; Lescoat A; Stratton R
Mol Aspects Med; 2024 Apr; 96():101252. PubMed ID: 38325132
[TBL] [Abstract][Full Text] [Related]
52. Mechanisms of kidney fibrosis and the role of antifibrotic therapies.
Deelman L; Sharma K
Curr Opin Nephrol Hypertens; 2009 Jan; 18(1):85-90. PubMed ID: 19077695
[TBL] [Abstract][Full Text] [Related]
53. Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy.
Castelino FV; Varga J
Curr Opin Rheumatol; 2014 Nov; 26(6):607-14. PubMed ID: 25191991
[TBL] [Abstract][Full Text] [Related]
54. Strategy for treatment of fibrosis in systemic sclerosis: Present and future.
Yanaba K
J Dermatol; 2016 Jan; 43(1):46-55. PubMed ID: 26782006
[TBL] [Abstract][Full Text] [Related]
55. Emerging targeted therapies in scleroderma lung and skin fibrosis.
Maurer B; Distler O
Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265
[TBL] [Abstract][Full Text] [Related]
56. Canonical Wnt signalling as a key regulator of fibrogenesis - implications for targeted therapies?
Dees C; Distler JH
Exp Dermatol; 2013 Nov; 22(11):710-3. PubMed ID: 24118232
[TBL] [Abstract][Full Text] [Related]
57. Systemic sclerosis: genetics and epigenetics.
Luo Y; Wang Y; Wang Q; Xiao R; Lu Q
J Autoimmun; 2013 Mar; 41():161-7. PubMed ID: 23415078
[TBL] [Abstract][Full Text] [Related]
58. Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition.
Mendoza FA; Piera-Velazquez S; Jimenez SA
Transl Res; 2021 May; 231():139-158. PubMed ID: 33422651
[TBL] [Abstract][Full Text] [Related]
59. Understanding Fibrosis in Systemic Sclerosis: Novel and Emerging Treatment Approaches.
Yin H; Li R; Lu L; Yan Q
Curr Rheumatol Rep; 2020 Sep; 22(11):77. PubMed ID: 32959073
[TBL] [Abstract][Full Text] [Related]
60. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.
Zhao M; Wu J; Wu H; Sawalha AH; Lu Q
Clin Rev Allergy Immunol; 2022 Apr; 62(2):273-291. PubMed ID: 33449302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
